Factor VIII:C concentrate purified from plasma using monoclonal antibodies: human studies

Area of Science:

• Hematology
• Immunology
• Biotechnology

Background:

• Conventional clotting factor concentrates are of intermediate purity, containing significant extraneous plasma proteins.
• Patients with severe hemophilia A and human immunodeficiency virus (HIV) require effective treatment options.
• Previous concentrates did not demonstrate immune-modulating effects in HIV-positive individuals.

Purpose of the Study:

• To evaluate the efficacy and safety of a novel, highly purified factor VIII concentrate.
• To assess the impact of this concentrate on immune function in HIV-seropositive hemophilia A patients.

Main Methods:

• Purification of factor VIII concentrate using monoclonal antibody affinity chromatography.
• Treatment of seven severe hemophilia A patients (HIV-positive, no inhibitor) for over 24 months.
• Monitoring of factor usage, clinical outcomes, CD4 counts, and immune responses (skin test anergy).

Main Results:

• The new concentrate demonstrated excellent efficacy with no allergic reactions or factor VIII antibody development.
• Mean CD4 counts stabilized in treated patients, and reversal of skin test anergy was observed.
• A comparison group on conventional concentrate showed no CD4 count stabilization and an increase in anergy.

Conclusions:

• Highly purified factor VIII concentrate is safe and effective for treating hemophilia A.
• This advanced concentrate may play a role in stabilizing immune function in HIV-seropositive patients.
• Further research is warranted to confirm the immunomodulatory potential of purified factor concentrates.